{"nbformat": 4, "nbformat_minor": 5, "cells": [{"cell_type": "markdown", "metadata": {}, "source": "### Data Analysis of Co-Mutations in KRAS G12C NSCLC\nThis analysis will utilize genomic datasets to identify co-mutations in patients with KRAS G12C mutations, focusing on their impact on treatment outcomes."}, {"cell_type": "code", "outputs": [], "metadata": {}, "execution_count": null, "source": "import pandas as pd\n\n# Load genomic data\ndata = pd.read_csv('path_to_genomic_data.csv')\n\n# Analyze co-mutations\nco_mutations = data[data['mutation_type'].isin(['KEAP1', 'STK11'])]\n\n# Summary statistics\nsummary = co_mutations.describe()"}, {"cell_type": "markdown", "metadata": {}, "source": "### Results\nThe analysis will provide insights into the prevalence of co-mutations and their correlation with treatment responses."}, {"cell_type": "code", "outputs": [], "metadata": {}, "execution_count": null, "source": "# Display summary statistics\nprint(summary)"}, {"cell_type": "markdown", "metadata": {}, "source": "\n\n\n\n***\n### [**Evolve This Code**](https://biologpt.com/?q=Evolve%20Code%3A%20This%20code%20analyzes%20genomic%20data%20to%20identify%20co-mutations%20in%20KRAS%20G12C%20NSCLC%20patients%2C%20aiding%20in%20personalized%20treatment%20strategies.%0A%0AIncorporate%20additional%20genomic%20datasets%20to%20enhance%20the%20robustness%20of%20co-mutation%20analysis.%0A%0AClinical-stage%20small%20molecule%20targeting%20KRAS%20G12C%20NSCLC%20Phase%201b%202%20co-mutations%20PD-1%20inhibitors%0A%0A%23%23%23%20Data%20Analysis%20of%20Co-Mutations%20in%20KRAS%20G12C%20NSCLC%0AThis%20analysis%20will%20utilize%20genomic%20datasets%20to%20identify%20co-mutations%20in%20patients%20with%20KRAS%20G12C%20mutations%2C%20focusing%20on%20their%20impact%20on%20treatment%20outcomes.%0A%0Aimport%20pandas%20as%20pd%0A%0A%23%20Load%20genomic%20data%0Adata%20%3D%20pd.read_csv%28%27path_to_genomic_data.csv%27%29%0A%0A%23%20Analyze%20co-mutations%0Aco_mutations%20%3D%20data%5Bdata%5B%27mutation_type%27%5D.isin%28%5B%27KEAP1%27%2C%20%27STK11%27%5D%29%5D%0A%0A%23%20Summary%20statistics%0Asummary%20%3D%20co_mutations.describe%28%29%0A%0A%23%23%23%20Results%0AThe%20analysis%20will%20provide%20insights%20into%20the%20prevalence%20of%20co-mutations%20and%20their%20correlation%20with%20treatment%20responses.%0A%0A%23%20Display%20summary%20statistics%0Aprint%28summary%29%0A%0A)\n***\n\n### [Created with BioloGPT](https://biologpt.com/?q=We%20are%20looking%20for%20a%20clinical-stage%20small%20molecule%20asset%20%28ideally%20Phase%201b%20or%20Phase%202-ready%29%20targeting%20KRAS%20G12C%20or%20another%20well-validated%20oncogenic%20driver%20in%20non-small%20cell%20lung%20cancer%20%28NSCLC%29.%20The%20asset%20should%20have%20strong%20preclinical%20or%20early%20clinical%20data%20showing%20tumor%20regression%2C%20ideally%20with%20a%20differentiated%20mechanism%20or%20improved%20safety%20profile%20over%20currently%20available%20KRAS%20inhibitors.%20We%20are%20particularly%20interested%20in%20candidates%20with%20co-mutation%20insights%20%28e.g.%2C%20KEAP1%2C%20STK11%29%20or%20combination%20potential%20with%20PD-1%2FL1%20inhibitors.%20The%20ideal%20licensing%20structure%20would%20be%20an%20exclusive%20global%20or%20regional%20deal%20%28North%20America%20or%20Europe%20preferred%29%2C%20with%20an%20option%20for%20co-development.)\n[![BioloGPT Logo](https://biologpt.com/static/icons/bioinformatics_wizard.png)](https://biologpt.com/)\n***"}], "metadata": {"title": "This code analyzes genomic data to identify co-mutations in KRAS G12C NSCLC patients, aiding in personalized treatment strategies.", "kernelspec": {"display_name": "Python 3", "language": "python", "name": "python3"}, "language_info": {"name": "python", "version": "3.13", "mimetype": "text/x-python", "codemirror_mode": {"name": "ipython", "version": 3}, "file_extension": ".py", "pygments_lexer": "ipython3"}, "author": "BioloGPT", "creation_date": "2025-03-27", "tags": ["KRAS G12C NSCLC assets", "biology", "bioinformatics"]}}